Medical devices, healthcare technology and the business of care
PMA approval · P980018

DAKO HERCEPTEST

Agilent Technologies Singapore (International) Pte , Ltd. · Decision date Sep 25, 1998

MEDTECHLEDGER EXPLANATIONP980018

What did the FDA approve?

The September 25, 1998 approval covers the DAKO HercepTest as a semi-quantitative immunohistochemical assay for detecting HER2 overexpression in routinely processed breast cancer tissues. The stated indication is as an aid in assessing patients for whom HERCEPTIN (trastuzumab) treatment is being considered.

The record does not describe a supplement, manufacturing change, or modification to an earlier PMA. No clinical trial data, performance metrics, or safety and effectiveness conclusions appear in the source statement. The device is classified under product code MVC as a HER-2/neu immunohistochemistry test system, with Agilent Technologies Singapore listed as the applicant.

FDA approval order statement

Approval for the DAKO Herceptest. This device is a semi-quantitative immunohistochemical assay to determine HER2 overexpression in breast cancer tissues routinely processed for histological evaluation. HercepTest is indicated as an aid in the assessment of patients for whom HERCEPTIN(R)(Transtuzumab) treatment is being considered.
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
Sep 25, 1998

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P980018
Regulatory pathway
Premarket approval application
Product code
MVC
Decision code
APPR
Decision date
Sep 25, 1998
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: SYSTEM, TEST, HER-2/NEU, IHC.

Product code
MVC
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P980018 received

    Application receipt date recorded by FDA.

  2. P980018 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P980018. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P980018

Product / regulatory recordCompanyPathwayDecision dateSource
HercepTestP980018/S027
Agilent Technologies Singapore (International) Pte , Ltd.PMA supplementSep 21, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Agilent Technologies Singapore (International) Pte , Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
# 1 Yishun Ave. 7, Singapore, 768923

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records